TOI promotes Dr. Daniel Virnich to President and Dr. Matthew Miller to COO

Oncology Institute, Inc.

Dr. Daniel Virnich promoted from COO to President, effective March 15, 2022.
Dr. Matthew Miller promoted from Chief Administrative Officer to COO, effective same date.
Board approved RSU/option grants: CEO Hively $678K RSU + $1.38M options; Virnich $263K RSU + $533K options; Dalgleish $201K RSU + $407K options.
Updated 2021 compensation: Hively $11.6M, Virnich $7.6M, Dalgleish $4.8M total pay.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Daniel Virnich

President

TOI · Oncology Institute, Inc.

Effective: 2022-03-15
Filed: March 7, 2022, 6:59 PM ET

On March 2, 2022, the Board of Directors of The Oncology Institute, Inc. (the "Company") promoted Dr. Daniel Virnich to serve as President of the Company, effective as of March 15, 2022.

Role change

Dr. Matthew Miller

Chief Operating Officer

TOI · Oncology Institute, Inc.

Effective: 2022-03-15
Filed: March 7, 2022, 6:59 PM ET

On March 2, 2022, the Board of Directors of the Company promoted Dr. Matthew Miller to succeed Dr. Virnich as Chief Operating Officer, effective as of March 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Daniel Virnich changed role as President at Oncology Institute, Inc..

Action: promoted
Role: President

Exact text from the filing

On March 2, 2022, the Board of Directors of The Oncology Institute, Inc. (the "Company") promoted Dr. Daniel Virnich to serve as President of the Company, effective as of March 15, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Matthew Miller changed role as Chief Operating Officer at Oncology Institute, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On March 2, 2022, the Board of Directors of the Company promoted Dr. Matthew Miller to succeed Dr. Virnich as Chief Operating Officer, effective as of March 15, 2022.

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-005246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.